Payment overview · 2025
General Payments
$579.36
24 reported records · 12 companies
Healthcare provider profile · identity verified
Mark Collins, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OSTERVILLE, MA · NPI 1255368494
Verified facts
What the public records show
CMS Open Payments records show Mark Collins, MD received $579.36 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Ozempic, Paxlovid, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HAVRIX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Havrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.10 | 14.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.63 | 14.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.45 | 9.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.82 | 9.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.20 | 9.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.45 | 9.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.12 | 8.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.27 | 7.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.62 | 5.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.76 | 4.3% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $24.63 | 4.2% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $19.31 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $579.36 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $83.63 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.45 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.24 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $54.20 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $52.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 27 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | HAVRIX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1190350374 |
Havrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 84 |
| Gabapentin | Gabapentin | 164 | 53 |
| Prednisone | Prednisone | 147 | 91 |
| Lisinopril | Lisinopril | 144 | 56 |
| Ozempic | Semaglutide | 139 | 35 |
| Omeprazole | Omeprazole | 138 | 53 |
| Lorazepam | Lorazepam | 103 | 41 |
| Trazodone Hcl | Trazodone Hcl | 103 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | 19 |
| Simvastatin | Simvastatin | 98 | 38 |
| Eliquis | Apixaban | 96 | 35 |
| Furosemide | Furosemide | 95 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 39 |
| Losartan Potassium | Losartan Potassium | 92 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 39 |
| Metformin Hcl | Metformin Hcl | 77 | 31 |
| Jardiance | Empagliflozin | 74 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 29 |
| Mirtazapine | Mirtazapine | 63 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 22 |
| Sertraline Hcl | Sertraline Hcl | 59 | 19 |
| Cephalexin | Cephalexin | 56 | 39 |
| Oxycontin | Oxycodone Hcl | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 53 | 25 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 46 | 46 |
| Diazepam | Diazepam | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | 21 |
| Atenolol | Atenolol | 45 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 31 |
| Finasteride | Finasteride | 40 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 14 |
| Spironolactone | Spironolactone | 38 | 14 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 14 |
| Carvedilol | Carvedilol | 34 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 30 | 30 |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Valsartan | Valsartan | 29 | 13 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 25 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 15 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | 11 |
| Azithromycin | Azithromycin | 23 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Famotidine | Famotidine | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | 11 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Yf-Vax | Yellow Fever Vaccine Live/Pf | 14 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Ipol | Poliomyelitis Vaccine, Killed | 12 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Havrix | Hepatitis A Virus Vaccine/Pf | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $579.36 · 24 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, ELIQUIS, EVENITY, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PROLIA, REXULTI, Rybelsus, SHINGRIX, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error